Suppr超能文献

经皮冠状动脉介入治疗后放射性造影剂所致肾病预测风险评分的验证

Validation of a predictive risk score for radiocontrast-induced nephropathy following percutaneous coronary intervention.

作者信息

Skelding Kimberly A, Best Patricia J M, Bartholomew Beth A, Lennon Ryan J, O'Neill William W, Rihal Charanjit S

机构信息

Division of Cardiology, Geisinger Medical Center, Danville, Pennsylvania, USA.

出版信息

J Invasive Cardiol. 2007 May;19(5):229-33.

Abstract

OBJECTIVE

We sought to externally validate the William Beaumont Hospital (WBH) risk score for radiocontrast-induced nephropathy (RCIN) following percutaneous coronary intervention (PCI). Background. RCIN is associated with increased mortality and morbidity following PCI and accounts for increased hospital costs and length of stay.

METHODS

A total of 4,814 PCI procedures were used for validation of the WBH risk score, using a >1.0 mg/dl increase in serum creatinine (Cr) as the definition of RCIN. Clinical and procedural details were identified within the Mayo Clinic PCI registry. Multiple imputation was used to impute values where missing. Five imputation sets were created and averaged to compute the final estimate.

RESULTS

Follow-up Cr was available in 3,213 (67%) of procedures and RCIN occurred in 1.9% of cases. Baseline Cr clearance was missing in 13%. All other risk factors used to calculate the risk score were missing in 25% of the procedures. The risk score has the ability to discriminate well between patients at low and high risk of post-PCI RCIN; c-statistic = 0.86. In-hospital mortality occurred in 6.6% (4/61) with RCIN vs. 1.2% (37/3152) without RCIN. The odds ratio for in-hospital mortality is 5.3 (95% CI, 1.9, 15.0; p = 0.002) for those with RCIN vs. those without.

CONCLUSIONS

The WBH risk score can identify patients at high and low risk of RCIN following PCI. Use of this risk score can identify patients at high risk of RCIN development and direct the use of preventative measures to the highest-risk population, improving patient outcome and prognosis.

摘要

目的

我们试图对经皮冠状动脉介入治疗(PCI)后放射性造影剂诱发肾病(RCIN)的威廉·博蒙特医院(WBH)风险评分进行外部验证。背景。RCIN与PCI后死亡率和发病率增加相关,并导致住院费用和住院时间增加。

方法

共有4814例PCI手术用于验证WBH风险评分,以血清肌酐(Cr)升高>1.0mg/dl作为RCIN的定义。在梅奥诊所PCI登记处确定临床和手术细节。对于缺失值,采用多重填补法进行填补。创建了五个填补集并进行平均以计算最终估计值。

结果

3213例(67%)手术有随访Cr数据,1.9%的病例发生了RCIN。13%的病例基线Cr清除率缺失。用于计算风险评分的所有其他风险因素在25%的手术中缺失。该风险评分能够很好地区分PCI后发生RCIN的低风险和高风险患者;c统计量=0.86。发生RCIN的患者院内死亡率为6.6%(4/61),未发生RCIN的患者为1.2%(37/3152)。发生RCIN的患者与未发生RCIN的患者相比,院内死亡的比值比为5.3(95%CI,1.9,15.0;p=0.002)。

结论

WBH风险评分可以识别PCI后发生RCIN的高风险和低风险患者。使用该风险评分可以识别RCIN发生风险高的患者,并将预防措施应用于最高风险人群,改善患者结局和预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验